Development and Validation of a Risk Score for Transthyretin Amyloidosis in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation: The GRECA-TAVI Registry - PubMed
7 hours ago
- #amyloidosis
- #TAVI
- #aortic stenosis
- Development of a risk score for predicting transthyretin cardiac amyloidosis (ATTR) in severe aortic stenosis (AS) patients undergoing TAVI.
- The GRECA-TAVI registry screened 500 patients using technetium-99m-labeled DPD or PYP bone scintigraphy across 12 hospitals.
- ATTR was diagnosed in 7.6% of patients (38 cases).
- Five key variables (age, sex, MWT, LVEF, and intracardiac device presence) formed an 8-point risk score.
- The risk score showed good discrimination (AUC=0.75-0.76) and calibration (slope=1.15).
- A score ≥4 identified patients with a 16% ATTR prevalence, capturing 73% of cases while screening only 36% of the cohort.
- Decision curve analysis demonstrated net clinical benefit over guideline-recommended or screen-all strategies.
- The tool enables selective screening, improving diagnostic yield and resource allocation.